本帖最后由 老马 于 2012-1-13 21:20 编辑 + L4 C) I" v& U" r% V3 M# k
" }: l# s5 W- H6 a9 E
爱必妥和阿瓦斯丁的比较6 e0 \1 g2 e6 y* ]4 W% [/ n( [
- o5 @1 s A1 k
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 F+ A8 |) g7 w4 K
8 W' x4 F0 Y& f3 Z* Y. P8 H3 x% a
3 ]/ h$ [* |) p" g) z9 Lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ _) a% C/ V" n/ k
==================================================. p& U4 F2 b$ v( D1 T
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)/ w/ n6 m$ I; K
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.+ D# F# @$ _* q& J& ]
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% f8 [2 z& x* ^
|